Skip to Content


Psychopharmacologic Drugs Advisory Committee; Cancellation

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Enhanced Content

Relevant information about this document from provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Food and Drug Administration, HHS.




The meeting of the Psychopharmacologic Drugs Advisory Committee scheduled for February 16, 2017, is cancelled. This meeting was announced in the Federal Register of December 27, 2016 (81 FR 95147). The meeting is no longer needed.

Start Further Info


Kalyani Bhatt, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, FAX: 301-847-8533, email:, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), and follow the prompts to the desired center or product area. Please call the Information Line for up-to-date information on this meeting.

Start Signature

Dated: January 11, 2017.

Janice M. Soreth,

Associate Commissioner for Special Medical Programs.

End Signature End Further Info End Preamble

[FR Doc. 2017-01170 Filed 1-18-17; 8:45 am]